Meet our team
Our leadership team has an extensive background in medical, orthopedics, neurosurgery, and spine surgery robotics.
Founders
Bertin Nahum
Bertin Nahum
Successful entrepreneur in Surgical Robotics :
Prior to Quantum Surgical, Bertin NAHUM founded Medtech SA (Rosa® Surgical Robot – neuro and spine surgery) in 2002, took the company public (IPO) in 2013 and sold it to Zimmer Biomet (NYSE: ZBH) in 2016.
Previously, he pioneered the development of robot-assisted solutions in various surgical specialties at Computer Motion Inc. (Zeus, AESOP – laparoscopic surgery) and Integrated Surgical Systems Inc. (ROBODOC – orthopedic surgery).
Bertin Nahum graduated from the National Institute of Applied Sciences (FR) and holds a Master of Science in Robotics and a Doctorate of Technology Honoris Causa from Coventry University (UK).
He was awarded the Legion of Honor in the rank of Chevalier in 2013.
Fernand Badano
Fernand Badano
Fernand has 25+ years of experience as Chief Operating Officer and on the Board of Directors of multiple innovative medical technology companies.
He served as General Manager and Board Director of Medtech SA.
Fernand Badano holds a PhD degree from National Institute of Applied Sciences (FR).
Lucien Blondel
Lucien Blondel
Sophie Roca
Leadership
Christophe Sibillin
Christophe Sibillin
Laetitia Messner
Laetitia Messner
Hervé Cointement
Jean-Michel Bredon
Jean-Michel Bredon
Jean-Michel BREDON has 10+ years of experience in the healthcare sector and 20+ years of experience in Information Systems and Organization Management.
Previous experience include the position of hospital director in charge of information systems and organization, as well as being the Referring Director of the Medical-Technical Department in several hospitals.
Stéphane Amalfi
Stéphane Amalfi
Yann Le Meur
Yann Le Meur
Andrew Zeringue
Thomas Klug
Board Members
Bertin Nahum
Bertin Nahum
Successful entrepreneur in Surgical Robotics :
Prior to Quantum Surgical, Bertin NAHUM founded Medtech SA (Rosa® Surgical Robot – neuro and spine surgery) in 2002, took the company public (IPO) in 2013 and sold it to Zimmer Biomet (NYSE: ZBH) in 2016.
Previously, he pioneered the development of robot-assisted solutions in various surgical specialties at Computer Motion Inc. (Zeus, AESOP – laparoscopic surgery) and Integrated Surgical Systems Inc. (ROBODOC – orthopedic surgery).
Bertin Nahum graduated from the National Institute of Applied Sciences (FR) and holds a Master of Science in Robotics and a Doctorate of Technology Honoris Causa from Coventry University (UK).
He was awarded the Legion of Honor in the rank of Chevalier in 2013.
Fernand Badano
Fernand Badano
Fernand has 25+ years of experience as Chief Operating Officer and on the Board of Directors of multiple innovative medical technology companies.
He served as General Manager and Board Director of Medtech SA.
Fernand Badano holds a PhD degree from National Institute of Applied Sciences (FR).
Lucien Blondel
Lucien Blondel
Frank Yu
Frank Yu
Frank is Founder, CEO and CIO of Ally Bridge Group (ABG), a leading global life sciences investment specialist having generated billions of dollars of value from its life science investments in China, the US and Europe, integrated between the private and public markets. ABG is dual-headquartered in New York and Hong Kong, also with teams in California and Israel. Frank and his team excel in leading high-impact life science transactions with a strong focus on the world’s most cutting-edge life science innovations at later stages, primarily in the US, and in deal-making between emerging technologies and industry giants, and across geographies.
Prior to founding and running Ally Bridge, Frank was a Managing Director at Goldman Sachs, then at Och-Ziff Capital where he was Head of China Investments. Previously, Frank had worked at Credit Suisse in Hong Kong and London, Moody’s and Thomson Financial in New York.
With a passion for art and world cultures and commitment to philanthropy, Frank serves on the Board of Trustees to the Solomon R. Guggenheim Foundation.
Kevin Reilly
Kevin Reilly
Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Special Investments, for the private equity strategy focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, Kevin was a Principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Kevin began his career in the Healthcare Investment Banking Group at Stifel Nicolaus. Kevin holds a BS in Finance and Information Systems from the University of Maryland.
Robert Thompson
Robert Thompson
Robert Thompson (Bob) is an accomplished marketing and business development leader and brings Quantum Surgical his experience in product development and commercialization in the medtech industry. He previously served as President-Ultrasound Siemens Healthineers, senior leadership positions at GE Healthcare and medical device start-ups.
Joseph de Vivo
Joseph de Vivo
Joseph de Vivo brings over 30 years of experience in medical device, robotics and digital health industries. He was most recently Executive Chairman of Caption Health, President of Hospitals and Health Systems for Teladoc Health and CEO of InTouch Health. He previously served as CEO of Angiodynamics and President of Smith & Nephew Orthopedics. Mr DeVivo currently serves as the Treasurer of the American Telemedicine Association and on the Board of Governors for St Jude Children’s Research Hospital.
Scientific Advisory Board
Prof. Steven D. Colquhoun (USA)
Prof. Steven D. Colquhoun (USA)
Prof. Steven D. Colquhoun is Liver Transplant Surgeon, specialized in robotic surgery. He completed fellowship training in both transplantation and surgical oncology at UCLA. He is board certified in both surgery and critical care, and has been more recently appointed Floyd C. Harrell, Jr MD Distinguished Chair, Surgery, Professor at Medical College of Georgia.
Dr. Colquhoun is involved in clinical and translational research aimed at improving both the diagnosis and treatment of hepatocellular carcinoma as well as other primary and metastatic liver tumors such as colorectal cancer and neuroendocrine tumors.
Prof. Thierry de Baere (FR)
Prof. Thierry de Baere (FR)
Prof. Thierry de Baere is Head of the Therapeutic Imaging Department (interventional radiology) at Gustave Roussy Cancer Center.
Prof. de Baère devotes his work to minimally invasive therapies in the treatment of kidney, lung, and liver cancers. He focuses mainly on intra-arterial therapies for primary and secondary liver tumors and percutaneous liver tumor ablation with radiofrequency and cryoablation.
Prof. Nishita Kothary (USA)
Prof. Nishita Kothary (USA)
Prof. Nishita Kothary is a Professor of Radiology in the section of Interventional Radiology at Stanford University Medical Center.
Dr. Kothary’s clinical practice primarily focuses on percutaneous and endovascular therapies for primary and metastatic liver cancer. Her research interests lie in radiogenomics and in the use of advanced imaging in the diagnosis and treatment of hepatocellular carcinoma (HCC).
Prof. David C. Madoff (USA)
Prof. David C. Madoff (USA)
Prof. David C. Madoff is Section Chief, Interventional Radiology at Yale New Haven Hospital and Vice Chairman for Clinical Research Department of Radiology and biomedical imaging at Yale School of medicine.
Previously, he was Vice Chairman for Academic Affairs and Professor of Radiology at Weill Cornell Medicine. From January 2011 to November 2015, David C. Madoff served as Chief of the Division of Interventional Radiology.
He is an internationally–recognized expert in Interventional Oncology.
Dr. David C. Madoff is a leader in academic Interventional Radiology and has been an invited speaker at numerous national and international meetings. He authored or co-authored over 100 peer-reviewed scientific articles, has written more than 30 book chapters and served as co-editor of three textbooks including the highly regarded textbook entitled Venous Embolization of the Liver: Radiologic and Surgical Practice and the newly released textbook entitled Clinical Interventional Oncology. David C. Madoff currently serves as Deputy Editor for RADIOLOGY, the flagship scientific journal of the Radiological Society of North America (RSNA) and served as Deputy Editor-in-Chief of the Journal of Vascular and Interventional Radiology from 2007 to 2010.
Dr. David C. Madoff is active in many of the major radiological societies including the Radiological Society of North America, the American Roentgen Ray Society, the Society of Interventional Radiology and the Association of University Radiologists. Based on his important contributions to the field, David C. Madoff was elected Fellow of the Society of Interventional Radiology in 2007 and Fellow of the American College of Radiology in 2015.
Prof. Luigi Solbiati (IT)
Prof. Luigi Solbiati (IT)
Luigi Solbiati worked from 1980 to 2015 at the General Hospital of Busto Arsizio (Varese), rising from Assistant Radiologist to Chairman of the Department of Oncology and Head of the Division of Interventional Oncologic Radiology.
He pioneered ultrasound-guided aspiration biopsies (1979), ethanol injection (1983), radiofrequency ablation with cool-tip electrodes (1995) and microwaves (2009) of solid tumors and fusion imaging for the guidance of interventional procedures (2003). In parallel, he has been serving as an adjunct Professor of “Techniques and Methods of Diagnostic Imaging” from 1988 to 2014 at the School of Radiology of the University of Milan.
He gave more than 480 scientific presentations at Meetings, Congresses and Courses in 23 countries. He has been Guest Lecturer at the Universities of San Diego, Zurich, Beijing, Hong Kong, New Delhi, Cairo, Vienna, Yale and at the Mayo Clinic (Rochester). Chairman of the 1st World Conference on Interventional Oncology (Cernobbio, Italy) in 2006. Chairman of the 1st Interventional Oncology Sans Frontieres Congress (IOSFC) (Cernobbio, Italy) in 2013.
Quantum Surgical is recruiting
At Quantum Surgical, we are recruiting the brightest minds and most creative innovators that thrive in a start-up environment.